Clinical Research Directory

Browse clinical research sites, groups, and studies.

1 clinical study listed.

Healthy volunteers

Filters:

HER2-expressing High-risk or Very High-risk NMIBC Without Visible Foci of Disease After TURBT

Tundra lists 1 HER2-expressing High-risk or Very High-risk NMIBC Without Visible Foci of Disease After TURBT clinical trial. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

NOT YET RECRUITING

NCT07100184

RC48 in Combination With Radiotherapy for HER2-Expressing NMIBC Patients

This study is an open, single-arm, single-center exploratory clinical study to explore the efficacy and safety of Disitamab Vedotin (RC-48) in combination with radiotherapy for the treatment of patients with HER2-expressing high-risk or very high-risk non-muscle invasive bladder cancer (NMIBC) without visible foci of disease after transurethral resection of bladder tumor (TURBT). The study plans to enroll 30 patients with high or very high risk HER2-expression NMIBC without visible lesions after TURBT. The study includes a screening period, a treatment period, and a survival follow-up period. This is a single-center study conducted at the Peking University First Hospital, and the PI is Prof. CuiJian Zhang.

Gender: All

Ages: 18 Years - Any

Updated: 2025-08-03

HER2-expressing High-risk or Very High-risk NMIBC Without Visible Foci of Disease After TURBT